Viking Therapeutics, Inc.
Clinical trials sponsored by Viking Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing metabolic and endocrine therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New weekly shot could help diabetics shed pounds Results expected Jul 2027 (estimated)
- New obesity drug VK2735 enters final testing phase Results expected Jul 2027 (estimated)
-
Can a pill speed up hip fracture recovery in seniors?
Disease control CompletedThis study tested an experimental drug called VK5211 in 108 adults aged 65 and older who had recently broken a hip. The goal was to see if the drug could help rebuild muscle mass lost after the injury. Participants took the drug or a placebo daily for 12 weeks, and researchers me…
Phase 2 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New daily pill shows promise for weight loss in phase 2 trial
Disease control CompletedThis study tested an experimental daily pill, VK2735, to help adults with obesity or overweight (plus a weight-related health issue) lose weight. About 280 participants took either the pill or a placebo for 13 weeks. The main goal was to see how much weight they lost and if the p…
Phase 2 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC